4+ day, 7+ hour ago   (23+ words) Evexta pairs ex-Merck drug with Roche’s giredestrant European Biotechnology Magazine Stay up to date every week with the european biotechnology newsletter....

4+ day, 12+ hour ago   (367+ words) AstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement. How it works: AZD4241 is an oral PROTAC designed to recruit the cell’s protein-disposal…...

5+ day, 12+ hour ago   (20+ words) AstraZeneca explores $400B combination with BMS European Biotechnology Magazine Stay up to date every week with the european biotechnology newsletter....

5+ day, 11+ hour ago   (306+ words) Guido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold. By the numbers: Oelkers joined Sobi in May 2017. Backstory: Oelkers inherited…...

5+ day, 5+ hour ago   (414+ words) Ipsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery. Why it matters: The decision removes one of Ipsen’s two experimental MAPK-pathway inhibitors for solid tumours…...

1+ week, 1+ day ago   (374+ words) Novo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales. Why it matters: The setback weakens Novo’s attempt to build a cardiovascular…...

1+ week, 1+ day ago   (439+ words) UK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million. Why it matters: The agreement takes IMPACT’s first approved medicine beyond China and gives Pharmanovia a near-market ovarian cancer asset…...

1+ week, 2+ day ago   (379+ words) London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments. Why it matters: The…...

1+ week, 4+ day ago   (473+ words) Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline. Why it matters: The financing gives Pentixapharm the funds to test whether a noninvasive scan…...

1+ week, 5+ day ago   (336+ words) Join us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders. BIO-Europe 2026 strengthens life science leadership, champions innovation, and fosters the global partnerships that drive our industry forward....